Di(2-ethylhexyl) phthalate-induced toxicity and peroxisome proliferator-activated receptor alpha: a review

Yuki Ito 1*, Michihiro Kamijima 1 and Tamie Nakajima 2

Abstract

The plasticizer di(2-ethylhexyl) phthalate (DEHP) has been widely used in the manufacture of polyvinyl chloride-containing products such as medical and consumer goods. Humans can easily be exposed to it because DEHP is ubiquitous in the environment. Recent research on the adverse effects of DEHP has focused on reproductive and developmental toxicity in rodents and/or humans. DEHP is a representative of the peroxisome proliferators. Therefore, peroxisome proliferator-activated receptor alpha (PPARα)-dependent pathways are the expected mode of action of several kinds of DEHP-induced toxicities. In this review, we summarize DEHP kinetics and its mechanisms of carcinogenicity and reproductive and developmental toxicity in relation to PPARα. Additionally, we give an overview of the impacts of science policy on exposure sources.

Keywords: Di(2-ethylhexyl) phthalate, Carcinogenesis, Reproductive toxicity, Developmental toxicity, Science policy

Introduction

Di(2-ethylhexyl) phthalate (DEHP, CAS No. 117-81-7) is the diester of phthalic acid (PA) and the branched-chain 2-ethyl-1-hexanol (2-EH). It is colorless, viscous, and soluble in lipophilic liquid. DEHP is the most commonly used plasticizer that makes plastic more flexible and elastic. It is used globally, and its shipping volume of 103,499 t accounted for approximately 50% of that of total phthalates in Japan in 2018 [1]. DEHP is widely used in various polyvinyl chloride (PVC) products such as plastic sheets, artificial leather, wire coverings, agricultural vinyl films, pastes, coating materials, medical products, and adhesive agents [1]. Because DEHP is contained in plastic materials without chemical bond, it can easily diffuse into the environment under high temperatures or during contact with hydrophobic materials, leading to ubiquitous environmental contamination. It can also be detected in air due to its use in many products, although little DEHP is intrinsically present in the air because it does not evaporate easily [2]. Moreover, DEHP binds to dust particles in air, binds strongly to soil, and dissolves very slowly in groundwater [3].

Given its omnipresence, there is a high likelihood that the general population will be exposed to DEHP. Recently, increasing attention has focused on the risks of DEHP, particularly in the fields in carcinogenesis and child health. In this review, we summarize the kinetics of DEHP and its mechanisms of carcinogenicity and reproductive and developmental toxicity in relation to nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα), which has been implicated in the mode of action of several types of DEHP-induced toxicities. Additionally, we provide an overview of the impacts of science policy on the sources of exposure.

Kinetics of DEHP

When DEHP is absorbed by the body, it is first metabolized (mainly by lipase) to mono(2-ethylhexyl) phthalate (MEHP) and 2-EH. A part of MEHP is then conjugated with UDP-glucuronate by UDP-glucuronosyltransferase (UGT) and excreted in the urine. The remaining MEHP is excreted directly in the urine or is oxidized by cytochrome P450 (CYP) 4A then further oxidized by alcohol dehydrogenase (ADH) or aldehyde dehydrogenase (ALDH) to dicarboxylic acid or ketones. 2-EH is metabolized primarily to 2-ethylhexanoic acid (2-EHA) via 2-ethyl-1-hexanal by the catalytic action of ADH and ALDH [4–6]. In these
enzymes, lipase activity shows prominent differences among mice, rats, and marmosets. An almost 160–240-fold difference has been reported, caused by the lower affinity of DEHP for lipase in marmosets and the significant differences in the \( V_{\text{max}}/K_{\text{m}} \) values of lipase for DEHP between the highest (in mice) and the lowest (in marmosets) activity [7]. These results correspond to the fact that lipase activity in humans is lower than that in mice, with only one seventh of the \( V_{\text{max}}/K_{\text{m}} \) value of lipase for DEHP [8]. In concordance with species differences in lipase activity, hepatic MEHP levels were significantly higher in mice and rats than in marmosets [9]. After DEHP treatment, species differences were also detected in the induction of peroxisome proliferator-activated receptor (PPAR) alpha-mediated enzymes, especially in peroxisomal enzymes such as 3-ketoacyl-CoA thiolase A and peroxisomal bifunctional protein [9, 10]. This was partly due to the different constitutive levels of PPARs and different formation levels of MEHP resulting from the hydrolysis of DEHP.

DEHP-hydrolyzing capacity depends on age and gestation. Microsomal lipase activities in the livers collected from PPAR\(\alpha\) wild-type (WT) fetuses on gestational day (GD) 18, pups on postnatal day 2 (PND2), and 23-month-old mice were approximately one quarter, one third, and one half of that in 3-month-old mice, respectively (Fig. 1). Intriguingly, lipase activity was 1.8-fold higher in pregnant dams than in postpartum ones, although no differences were observed in the activity between fetuses and pups [11]. In concordance with their mother’s lipase activity, MEHP concentrations were from 1.5 to 1.7-fold higher in fetuses and their mother dams than in PND2 pups and their mother dams, respectively, after exposure to 0.05% DEHP [11], suggesting that MEHP levels in the blood of the offspring (either fetus or pup) might be related to their mothers’ hepatic lipase activity. Exposure via the placenta in fetuses and milk in pups as well as the production of MEHP in the offspring was implied. UGT activity in fetuses was half of that in pups [11], suggesting that the internal dosage of an active metabolite, MEHP, was likely to be higher in fetuses than in pups. In humans, inter-individual differences in the metabolism of DEHP have been reported, which were greater than the species differences between mice and humans [12]. Inter-individual differences in DEHP metabolism in humans may therefore be more crucial than species differences and thus more important in risk assessment.

Possible involvement of PPAR\(\alpha\) in DEHP metabolism was suggested in our study (Fig. 2). Excreted amounts of metabolites such as mono(2-ethyl-5-oxoheptyl)phthalate (5oxo-MEHP), mono(2-ethyl-5-carboxypentyl)phthalate (5cx-MEPP), and phthalic anhydride (PHA) in 24-h urine differed among WT, Ppara-null (KO), and PPAR\(\alpha\)-humanized Tet-Off (HT) mice with KO mouse backgrounds after 0.1% DEHP exposure for 8 weeks were shown in Fig. 2. The amounts of 5cx-MEPP were higher in HT and KO mice than in WT mice. The expression of PPAR\(\alpha\) in HT mice was comparable [13] or higher [14] than that in WT mice. This suggests that the functional differences of PPAR\(\alpha\) between humans and mice affect the metabolite composition profile, and PPAR\(\alpha\) might be involved in the pathway of 5cx-MEPP production. Interestingly, 5oxo-MEHP and 5cx-MEPP levels were more dominant in humans than in mice [12]. The relatively weak function of human PPAR\(\alpha\) compared with that in rodents [10, 14, 15] presumably promotes 5cx-MEPP production via enhancing the activity of the enzyme that catalyzes the production of this metabolite. In other words, if the PPAR\(\alpha\) function is weak or absent, the enzyme involved in 5cx-MEPP production might be activated.

**PPAR\(\alpha\) agonist**

PPARs are members of the nuclear hormone receptor superfamily and consist of three subunits, PPAR\(\alpha\), PPAR\(\beta/\delta\), and PPAR\(\gamma\) [16]. One of three isoforms, PPAR\(\alpha\) is mainly expressed in organs that are critical in fatty acid catabolism, such as the liver, heart, and kidneys [17]. Thus, this nuclear receptor is primarily involved in the regulation of fatty acid metabolism. In addition to this function, PPAR\(\alpha\) also has various other functions including the promotion of gluconeogenesis, lipogenesis, ketogenesis, and anti-inflammatory effects [18]. The mono- and dicarboxylic acid metabolites of DEHP, not DEHP itself, act as ligands for PPAR\(\alpha\) and PPAR\(\gamma\) [19] and have potentially adverse effects on the liver, kidneys, heart, and reproductive organs. After ligand binding, PPAR/rexinoid X receptor heterodimers bind to specific DNA sequences called PPAR response elements (PPREs) in the nucleus and exert various biological functions.
Therefore, DEHP potentially alters these functions. In addition, it is presumed that the binding activity of the PPARα/PPRE also depends on species-specific PPARα function or expression levels (Fig. 3).

Toxicity
DEHP has been shown to cause cancer, reproductive, developmental, nerve, and immune toxicities, and endocrine disruption effects in rodents [2]. Of these toxicities, we focus on the carcinogenicity and reproductive and developmental toxicities.

Carcinogenicity
Among DEHP-induced toxicities [20–22], hepatic carcinogenicity was the most important issue reported in the past three decades. The cancer risk assessments conducted by many different regulatory authorities have changed over time with the advent of detailed mechanistic information on the involvement of PPARα in the non-genotoxic carcinogenic process, in which metabolites of DEHP activate PPARα signaling as mentioned above. In 1992, based on the hepatocarcinogenesis in rodents (predominantly from National Toxicology Program (NTP)
As mentioned above, although the expression of human PPAR is similar to that in rodents [13], it is less active against carcinogenesis than that in rodents [10, 14, 15]. However, factors other than PPAR have been suggested to be involved in DEHP hepatocarcinogenesis [36–40]. Some studies pointed out the involvement of non-PPARα pathways as well as PPARα-dependent pathways in DEHP-induced carcinogenicity [32, 41–43]. Of them, the activation of nuclear factor kappa B (NFκB) and other nuclear receptors such as constitutive androstane receptor (CAR) was thought to be possible molecular targets. PPARα exhibits anti-inflammatory activity in WT mice since it represses NFκB. The study using KO mice exposed to DEHP for 22 months showed a dose-dependent increase of NFκB and elevated plasma alanine aminotransferase in KO mice with hepatic tumors [32]. Chronic inflammation promotes genetic and epigenetic aberrations in tumor pathogenesis [44]. A recent paper implied that two modes of action (MOA) were involved in the DEHP-induced tumors in KO mice: steatosis, accumulated in the aged KO mice, played a role in the onset of inflammation in which inflammatory molecules such as NFκB were involved, or increased activation of CAR-related signaling contributed to liver tumors via cell proliferation and foci formation [45]. Dietary DEHP exposure for 2 weeks activated CAR much more strongly in KO mice than in WT mice [46]. It is not known if the weak activation of CAR in WT mice leads to key events downstream other than a weak activation of some CAR-dependent genes, similar to in KO mice, in addition to PPARα-dependent MOA [45].

Although little epidemiological evidence supports the association between DEHP and liver cancer in humans, the IARC concluded that “the human relevance of the molecular events leading to DEHP-induced cancer in several target tissues (e.g., the liver and testis) in rats or mice could not be ruled out” and decided to upgrade DEHP to group 2B in 2012 [47]. At present, the expected key events in DEHP-induced hepatocarcinogenesis are as follows: (1) PPARα activation, (2) alteration in cell growth pathways, (3) alteration in hepatocyte growth including the effects on proliferation and apoptosis, and (4) clonal expansion of preneoplastic-initiated hepatocytes, which (5) leads to the increases in hepatocellular adenomas and carcinomas [45]. NFκB is thought to be a modulating factor that could modulate the dose-response behavior, the probability of inducing one or more key events, or the adverse outcome [45].

Reproductive and developmental toxicity
For many years, DEHP was suspected to have reproductive toxicity in mice and in vitro studies [21, 48–50], but without being classified, and in the 1990s, DEHP was also suspected to disrupt the estrogen levels in in vitro studies and female adult rats [51–53]. However, studies have supported the hypothesis that DEHP can...
harm the reproductive system due to an anti-androgenic effect [54], and these findings have placed DEHP on the EU list of dangerous substances, where it is now classified as a substance which may be regarded to impair fertility and cause developmental toxicity in humans (category 2) [55]. The Japan Society for Occupational Health classified DEHP in group 1 “substances known to cause reproductive toxicity in humans” [56]. In animal studies, DEHP exposure induces testicular morphological changes (especially in Leydig and Sertoli cells), reproductive tract developmental anomalies, sperm damage, disruption of endocrine hormones, changes in the birth sizes of offspring, and anogenital distance [54, 57, 58]. Some epidemiological studies have reported a negative association between DEHP exposure and steroid hormones in the cord blood. In Japan, maternal blood MEHP levels were associated with reduced levels of testosterone (T)/estradiol (E2), progesterone (P4), inhibin B, and insulin-like factor 3 in male cord blood [59], with reduced cortisol and cortisone levels and a lower glucocorticoid/adrenal androgen ratio, but increased dehydroepiandrosterenedione (DHEA) levels and a higher DHEA/androstenedione ratio [60]. In Taiwan, maternal urinary levels of DEHP metabolites were negatively correlated with the free T and T/E2 levels in the cord blood [61]. Child-only or both maternal and child DEHP metabolite levels were associated with decreased levels of free T in males or decreased levels of P4 in females, respectively [62]. Additionally, some epidemiological studies suggest an inverse association between DEHP exposure and neurodevelopmental effects [63–65].

In utero exposure to DEHP caused maternal malnutrition, such as PPARα-dependent decreases in serum triglycerides and essential fatty acids. However, these findings were not observed in the offspring in mice. While serum glucose levels in the pups decreased PPARα-dependently, such changes were not observed in their dams [66–71]. However, this phenomenon has not been well-investigated; thus, it remains unknown whether unbalanced nutrition caused by DEHP in utero and during infancy is followed by an increased risk of lifestyle diseases. An epidemiological study also reported that DEHP suppressed leptin concentrations via PPARα in offspring [72], resulting in increased food consumption after weaning [60]. The impacts of DEHP exposure on offspring in their later lives should be clarified.

Regarding the reproductive toxicity, various mechanisms, including anti-androgenic effects, have been proposed but not yet proven. The mechanism of the developmental toxicity of DEHP is also still unclear, although the involvement of PPARα has been suggested [70, 73]. The existence of PPARα-independent pathways in the reproductive toxicity of DEHP was reported at higher dosages [74, 75].

**Exposure sources and regulation**

Reportedly, estimated daily DEHP intake was 87–89% from food, 9.5–9.7% from indoor air, and 1.4–2.0% from drinking water in a Canadian population [47], and the intake from ambient air and soil was considerably lower. Thus, the general population is mainly exposed to DEHP via food, particularly fatty foods such as milk, including breast milk. Fish, fats, oils, and freeze-dried foods can also be highly contaminated with DEHP [76].

With regard to food packaging, the use of DEHP in the material that comes into contact with food has already been restricted under Commission Directive 2007/19/EC of March 30, 2007, amending Directive 2002/72/EC relating to plastic materials and articles likely to come into contact with food [77]. In Japan, the use of DEHP in PVC materials used for the packaging of foods containing edible fats and oils is avoided to prevent its migration into food. Furthermore, its use is prohibited in the manufacture of toys [78]. In 2008, as a measure to reduce exposure and protect children's health, the US Congress passed the Consumer Product Safety Improvement Act, which includes a federal ban on phthalates in toys and child products. This latest legislation prohibits the use of eight phthalates in the manufacture of children's products [79]. Similarly, DEHP and other phthalates are already restricted through entry 51 of Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the European Council, which legislates that toys containing several phthalates, including DEHP, with a cumulative concentration greater than 0.1% by weight of the plasticized material cannot be placed on the EU market [80]. These restrictions also apply to the cables or spare parts used for the repair, reuse, updating of functionalities, or upgrading of the capacity of electrical and electronic equipment placed on the market after July 22, 2019, and also to the medical devices, including in vitro medical devices, as well as monitoring and control instruments, including industrial monitoring and control instruments, placed on the market after July 22, 2021 [81].

The US Food and Drug Administration (FDA) believes that the greatest concern is for very young male infants who are critically ill and have prolonged exposure to multiple devices containing DEHP [82]. Additionally, the reproductive development of male fetuses (through exposure to their mothers) and peripubertal males would also be at risk. The NTP has reached a similar conclusion [83].

In contrast, there is a little concern for adults receiving intravenous solutions or undergoing peritoneal dialysis, who were previously thought to be a high-risk group.

So far, a number of government agencies and expert panels in Japan, the USA, Canada, and Europe, have reviewed the safety of DEHP in medical devices and toys. Each of these agencies and expert panels has found that
DEHP exposure from some medical procedures may pose a risk to the patients’ health and recommended restricting the use of phthalates, including DEHP, in medical devices (Ministry of Health, Labour and Welfare in Japan; European Directive 2007/47/CE; FDA Safety Assessment and a Public Health Notification; Health Canada expert advisory panel on DEHP in medical devices). Medical device manufacturers were therefore forced to quickly find alternatives to DEHP to maintain the elasticity of PVC nutrition tubes, infusion sets, and hemodialysis lines. Several replacement plasticizers, the so-called alternative to DEHP plasticizers such as tri-octyl trimellitate (TOTM), 1,2-cyclohexane dicarboxylic acid diisononyl ester (DINCH), and di(2-ethylhexyl)cyclohexan-1,4-dicarboxylate (DEHCH), are currently incorporated in modern medical devices [84–86].

In 2002, the Ministry of Health, Labour and Welfare in Japan recommended the immediate precautionary replacement of all DEHP-softened PVC medical devices in feeding tubes for premature infants and newborns and in dialyzer blood circuits with alternative products. In addition, it was also mentioned that DEHP exposure from transfusion tubes and blood oxygenator tubes should also be minimized when alternatives are available. After this admonition, the changes in MEHP levels between the cord serum and the serum of the 1-month-old newborns in a neonatal intensive care unit (NICU) were reduced significantly by the replacement of PVC feeding tubes with PVC-free feeding tubes (pre-admonition, from 15 μg/L (median) in the cord blood to 185 μg/L in the sera at aged 28 days; post-replacement, from 10 μg/L in the cord blood to 79 μg/L in the sera at aged 28 days) [87, 88]. In 2010, we examined the extraction tests using the medical tubes running in a certain hospital. No DEHP was detected in the feeding tubes for neonates or the transfusing tubes for dialyzed patients, some of which contains TOTM instead of DEHP, although DEHP was detected in blood oxygenator tubes. Importantly, in some cases, when difficulties arose while inserting the tubes, the tubes containing DEHP were used for the neonates [85]. Even when using PVC-free tubes, serum MEHP levels in infants in the NICU were higher than those in the dialyzed patients before a hemodialysis session (Fig. 4). A possible causal factor responsible for the high serum levels of MEHP in infants might be the low activity of UGT in young children [90]. In addition to the medical devices, DEHP contamination in packed food and bottled water was reported, but at considerably lower levels than those putting patients with chronic illnesses at risk [91].

**Recent topics**

Many studies show carcinogenicity and reproductive and developmental toxicity in rodents, but human data is limited. A food scandal occurred in Taiwan in 2011 because DEHP had been intentionally used in food products [92].

**Fig. 4** Serum MEHP concentrations in the cord and corresponding PND28 infant in NICU (n = 49) and dialyzed patients (n = 110). PVC-free tubes were used for feeding the infants in NICU [87, 88]. The serum from the dialyzed patients was collected before a hemodialysis session using plasticizer-free tubes with written informed consent. Data for the serum MEHP concentrations after the hemodialysis session have been presented in our previous paper [89]. The analytical methods have been described elsewhere [7]. *p < 0.05 compared with the other groups.

Further longitudinal epidemiological data will contribute to the risk assessments of DEHP in humans [93].

World production of plastic containing polyethylene (PE), polypropylene, PVC, polystyrene, polyamide, chlorinated PE, and chlorosulfonated PE increased drastically in the last two decades [94], while that in Japan, decreased [95]. Recently, large amounts of these plastics end up in the ocean as so-called microplastics. The microplastic-associated organic plastic additives contain phthalates including DEHP [96]. For all organisms, the combined intake from food and water was the main route of exposure to DEHP with a negligible input from plastic, while a very small increase in the internal concentrations of DEHP was observed in benthic invertebrates [97].

**Conclusions**

In this review, we summarized the mechanisms of carcinogenicity and reproductive and developmental toxicity in relation to PPARα. Additionally, we gave an overview of the impacts of science policy on the exposure sources. DEHP use has been restricted because of the potential adverse effects, and DEHP exposure levels in people at higher risk have thereby certainly been reduced.

**Abbreviations**

+/-: Heterozygous; +/+: Homozygous; 2cx-MMHP: Mono[2-(carboxymethyl)hexyl]phthalate; 2-EH: 2-Ethyl-1-hexanol; 2-EHA: 2-Ethylhexanoic acid; Scc-MEP: Monono(2-ethyl-5-carboxypropyl)phthalate; Soxo-MEHP: Mono[2-ethyl-5-oxo-hexyl]phthalate; ADH: Alcohol dehydrogenase; ALDH: Aldehyde dehydrogenase; CAR: Constitute androstane receptor; Cr: Urinary creatinine; CYP: Cytochrome P450; DBHCH: Di(2-ethylhexyl)cyclohexan-1,4-dicarboxylate; DEHP: Di(2-ethylhexyl) phthalate; DHEA: Dehydroepiandrosterone; Dinch: 1,2-Cyclohexane dicarboxylic acid diisononyl ester; E2: Estradiol; FDA: Food and Drug Administration; GD: Gestational day; HT: PPARα-humanized mouse; IARC: International Agency for Research on Cancer; KO: Pparα-null mouse; MEHP: Mono[2-(carboxymethyl)hexyl]phthalate; MG: Myeloid; MMHP: Mono[2-(methylthio)hexyl]phthalate; ND: No detect; TM: Transgenic mice; TOTM: Tri-octyl trimellitate; Xing: Xingzhong Wang; XZ: Xiangyu Zhu; YH: Yukinori Hasegawa; YQ: Ying Qin; ZS: Zhiqiang Sun; ZH: Zhao Hang.
ethylhexyl) phthalate; NFkB: Nuclear factor kappa B; NCU: Neonatal intensive care unit; NTP: National Toxicology Program; P4: Progesterone; PE: Polyethylene; PHA: Phthalic anhydride; PND: Postnatal day; PPAR: Peroxisome proliferator-activated receptor; PVC: Polyvinyl chloride; T: Testosterone; TOTM: Tri-octyl trimellitate; UGT: UDP-glucuronosyltransferase; WT: Wild-type mice

Acknowledgements

N/A

Authors’ contributions

YI, MK, and TN wrote the manuscript. All authors have read and approved the final manuscript.

Funding

The work in this review was partially funded by Health and Labor Sciences Research Grants from the Ministry of Health Labour and Welfare, Japan (200939055A); Grants-in-Aid from Food Safety Commission, Japan (No. 1002); and Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (B. 14370121, B. 17390169, C.25460808).

Availability of data and materials

Please contact the authors for data requests.

Ethics approval and consent to participate

The animal experiments were conducted according to the Guidelines for Animal Experiments of the Nagoya University Animal Center. The study protocol for human data was approved by the Ethics Committees of Nagoya University Graduate School of Medicine and Nagoya City University Graduate School of Medical Sciences. All the study participants gave their written consent in accordance with the Declaration of Helsinki.

Consent for publication

N/A

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.

2College of Life and Health Sciences, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi 487-8501, Japan.

Received: 26 March 2019 Accepted: 28 June 2019

Published online: 06 July 2019

References

1. Japan Plasticizer Industry Association. Statistical database. 2018 http://www.kasozai.gr.jp/data/ Accessed 25 Feb 2019.

2. Rowdhval SSS, Chen J. Toxic effects of di-2-ethylhexyl phthalate: an overview. Bioned Res Int. 2018;2018:1750368.

3. Rosle P., Madsen PL, Thyme JB, Henrikson K. Degradation of phthalate and di-(2-Ethylhexyl)phthalate by indigenous and inoculated microorganisms in sludge-amended soil. Appl Environ Microbiol. 1998;64:4711–9.

4. Albro PW. Absorption, metabolism, and excretion of di-(2-ethylhexyl) phthalate by rats and mice. Environ Health Perspect. 1986;65:293–8.

5. Albro PW, Corbett JT, Schroeder JL, Jordan S, Matthews HB. Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ Health Perspect. 1982;24:19–25.

6. Albro PW, Lavenhar SR. Metabolism of di-(2-ethylhexyl) phthalate. Drug Metab Rev. 1989;21(1):13–34.

7. Ito Y, Yokita H, Wang R, Yamashita O, Ichiha G, Wang H, et al. Species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) in several organs of mice, rats, and marmosets. Arch Toxicol. 2005;79:147–54.

8. Ito Y, Tomizawa M, Suzuki H, Okamura A, Ohtani K, Nunome M, et al. Fenitrothion action at the gonadoblastoma system leading to spermatotoxicity in Wistar rats. Toxicol Appl Pharmacol. 2014;279:331–7.

9. Ito Y, Yamashita O, Kuruta Y, Kamijima M, Aoyama T, Nakajima T. Induction of peroxisome proliferator-activated receptor alpha (PPARalpha)-related enzymes by di(2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not marmosets. Arch Toxicol. 2007;81(3):219–26.

10. Ito Y, Nakamura T, Yanagiba Y, Ramdhan DH, Yamagishi N, Naito H, et al. Plasticizers may activate human hepatic peroxisome proliferator-activated receptor alpha less than that of a mouse but may activate constitutive androstane receptor in liver. PPAR Res. 2012; 2012:201284.

11. Hayashi Y, Ito Y, Yanagiba Y, Kamijima M, Naito H, Nakajima T. Differences in metabolite burden of di(2-ethylhexyl)phthalate in pregnant and postpartum dams and their offspring in relation to drug-metabolizing enzymes in mice. Arch Toxicol. 2012;86(4):563–9.

12. Ito Y, Kamijima M, Hasegawa C, Tagawa M, Kawai T, Miyake M, et al. Species and inter-individual differences in metabolic capacity of di-2-ethylhexylphthalate (DEHP) between human and mouse livers. Environ Health Prev Med. 2014;19(2):17–25.

13. Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 2017;136:75–84.

14. Nakamura T, Ito Y, Yanagiba Y, Ramdhan DH, Kono Y, Naito H, et al. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha. Toxicology. 2009;265(1):227–33.

15. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. The PPAR alpha humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci. 2008;101(1):132–9.

16. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421–4.

17. Issermann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:626–30.

18. Mandall S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004;61(4):393–416.

19. Maloney EK, Wxaxman DJ. trans-Activation of PPARa and PPARy by structurally diverse environmental chemicals. Toxicol Appl Pharmacol. 1999; 161(2):209–18.

20. Kluwe MM, Haseman J, Douglas J, Huff JE. The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice: J Toxicol Environ Health. 1982;10(4-5):797–815.

21. Melnick RL, Morrissey RE, Tomaszewski KE. Studies by the National Toxicology Program on di(2-ethylhexyl)phthalate. Toxicol Ind Health. 1987; 3(2):199–118.

22. National Toxicology Program. Di(2-ethylhexyl) phthalate, in Report on Carcinogens. 2016. http://ntp.niehs.nih.gov/go/roc.

23. National Toxicology Program, Perinatal toxicology bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed studies). Nat Toxicol Program Tech Rep Ser. 1982;217:1–127. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono29.pdf.

24. U.S. Environmental Protection Agency, Integrated Risk Information System (IRIS) on di(2-ethylhexyl)phthalate. National Center for Environmental Assessment OoRaD. Washington, DC. 1999. https://cfpub.epa.gov/ncea/iris/docs/documents/subst/0014_summary.pdf.

25. International Agency for Research on Cancer, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, in some industrial chemicals and dyestuffs. 1982. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono29.pdf.

26. Japan Society for Occupational Health. Occupational exposure limits. Jpn J Ind Health. 1992;34:363–84.

27. Doull J, Cattley RA, Ecombe C, Lake BG, Swenberg J, Wilkinson C, et al. Cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol. 1999;29(3):327–57.

28. International Agency for Research on Cancer, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Some Industrial Chemicals. 2000. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono274.pdf.

29. Scientific Committee on Toxicity eateC, Opinion on the results of a second risk assessment of bis(2-ethylhexyl)phthalate (DEHP) human health part. 2004. https://ec.europa.eu/health/archive/ph_risk/commission/isc_docs/documents/out214_en.pdf.

30. Hasmell SC, James NH, Macdonald N, Soames AR, Roberts RA. Species differences in response to di(2-ethylhexyl)phthalate suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression. Arch Toxicol. 2000;74(2):85–91.

31. Pugh G Jr, Isenberg JS, Kamendulis LM, Ackley DC, Clare LJ, Brown R, et al. Effects of di-isonyanophenylphthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys. Toxicol Sci. 2000;55(1):1181–8.
32. Ito Y, Yamanoshita O, Asaeda N, Tagaya Y, Lee CH, Aoyama T, et al. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway. J Occup Health. 2007;49(3):172–82.

33. Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health. 2008;50(2):169–80.

34. Voss C, Zerban H, Bannasch P, Berger MR. Lifelong exposure to di-(2-ethylhexyl)phthalate induces tumors in liver and testes of Spaguage-Dawley rats. Toxicology. 2005;206(3):359–71.

35. David RM, Moore MR, Finney DC, Guest D. Chronic toxicity of di-2-ethylhexylphthalate in rats. Toxicol Sci. 2005;82(2):433–43.

36. Melnick RL. Peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)? Environ Health Perspect. 2001;109(5):347–42.

37. Melnick RL. The IARC evaluation of di(2-ethylhexyl)phthalate (DEHP); a flawed decision based on an untested hypothesis. Int J Occup Environ Health. 2002;8(2):284–5.

38. Melnick RL. Suppression of crucial information in the IARC evaluation of di(2-ethylhexyl)phthalate. PPAR Res. 2008;2008:759761.

39. Gray LE Jr, Ostby J, Furr J, Price M, Veeramachaneni DN, Parks L. Perinatal exposure to bis(2-ethylhexyl)phthalate diesters in males. Off J Eur Communities. 2001; L 225: 1-333.

40. Davis BJ, Maronpot RR, Heindel JJ. Di(2-ethylhexyl) phthalate suppresses blood glucose and leptin levels in the offspring of wild-type mice. Toxicology. 2019;415:49–59.

41. Jia X, Harada Y, Tagawa M, Naito H, Hayashi Y, Yetti H, et al. Prenatal exposure to di(2-ethylhexyl) phthalate and subsequent infant and child health effects. Food Safety. 2015;3(3):70–83.

42. Hayashi Y, Ito Y, Nakajima T. Relationship of maternal malnutrition caused by di(2-ethylhexyl) phthalate exposure with lifestyle in offspring. Nihon Eiseigaku Zasshi. 2012;67(1):22–5.

43. Hayashi Y, Ito Y, Naito K, et al. Effects of exposure to di(2-ethylhexyl)phthalate during fetal period on next generation. Nihon Eiseigaku Zasshi. 2014;69(3):558–66.

44. Takashima K, Itoh S, Itoh Y, et al. Prenatal exposure to di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: the Hokkaido Study. Sci Total Environ. 2017;581:582–297–304.

45. Lin S, Ku HY, Su PH, Chen JW, Huang PC, Angerer J, et al. Prenatal exposure to phthalate does not increase cancer risk in children in Taipei, Taiwan. Environ Health Perspect. 2011;119(10):1495–500.

46. Hayashi Y, Ito Y, Nakajima T. PPARalpha-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Arch Toxicol. 2018;92(1):83–119.

47. Corton JC, Peters JM, Klaunig JE. The PPARalpha-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Environ Health Perspect. 2001;109(11):1664–72.

48. Ward EM, Schulte PA, Stralk K, Hopf NB, Caldwell JC, Carreon T, et al. Research recommendations for selected IARC-classified agents. Environ Health Perspect. 2010;118(10):1355–62.

49. Ray A, Peters JM, Cunningham ML. Modes of action and species-specific effects of di(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol. 2006;36(5):459–79.

50. Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):51.

51. Corton JC, Peters JM, Klaunig JE. The PPARalpha-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Environ Health Perspect. 2001;109(11):1664–72.

52. Ren H, Aleuxomes LM, Wood C, Vallanat B, George MH, Klaassen CD, et al. Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. Toxicol Sci. 2010;113(1):45–59.

53. International Agency for Research on Cancer. Some chemicals present in industrial and consumer products, food and drinking-water. 2013. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono101-006.pdf

54. Thomas JA, Thomas MJ. Biological effects of di-(2-ethylhexyl) phthalate and other phthalic acid esters. Crit Rev Toxicol. 1984;13(4):283–341.

55. Japan Society for Occupational Health. Occupational exposure limit (in Japanese). Sanyo Eisegaku Zasshi. 2015;57:270–4.

56. Japan Society for Occupational Health. Occupational exposure limit (in Japanese). Sanyo Eisegaku Zasshi. 2015;57:270–4.
79. The US 110th Congress. Consumer Product Safety Improvement Act of 2008. Public law 110-314, 2008; Available from: https://www.cpsc.gov/s3fs-public/cpsia.pdf.
80. European Communities. Entry 51 of Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council. 2006.
81. EU2015/863 R. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2015:137:FULL&from=EN.
82. The US Food and Drug Administration. DEHP in plastic medical devices. [cited 2019 March 22]; Available from: https://bcgreencare.ca/system/files/resource-files/Choosing%20a%20Medical%20Device%20%20DEHP%20in%20Plastic%20Medical%20Devices.pdf.
83. National Toxicology Program Center for the evaluation of risks to human reproduction, NTP-CERHR monograph on the potential human reproductive and developmental effects of di(2-ethylhexyl)phthalate (DEHP). 2006.
84. Bernard L, Decaudin B, Leceouer M, Richard D, Bourdeaux D, Cueff R, et al. Analytical methods for the determination of DEHP plasticizer alternatives present in medical devices: a review. Talanta. 2014;129:39–54.
85. Ito Y, Grant report #200939055A in Japanese, in Health and Labor Sciences Research Grants 2009.
86. Hughes BJ, Cox K, Bhat V. Derivation of an oral reference dose (RfD) for di-2-ethylhexyl cyclohexan-1,4-dicarboxylate (DEHCH), an alternative to phthalate plasticizers. Regul Toxicol Pharmacol. 2018;92:128–37.
87. Minakami H, Grant report #200736012B in Japanese, in Health and Labor Sciences Research Grants 2008.
88. Konishi S, Cho K, Okajima S, Minakami H, Yamada T, Shono N. Effects of phthalate exposure on neonates Japan Society of Perinatal and Neonatal Medicine proceedings in Japanese. 2007; 43(2): 410.
89. Kamijo Y, Hara K, Nakajima T, Kono K, Takahashi K, Ito Y, et al. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J Am Soc Nephrol. 2007;18(1):176–88.
90. Strassburg CP, Strassburg A, Kneip S, Barat A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259–65.
91. Erythropel HC, Maric M, Nicoll JA, Leask RL, Yargeau V. Leaching of the plasticizer di(2-ethylhexyl)phthalate (DEHP) from plastic containers and the question of human exposure. Appl Microbiol Biotechnol. 2014;98(4):9967–81.
92. Tsai HJ, Chen BT, Wu CF, Wang SL, Huang PC, Tsai YC, et al. Intake of phthalate-tainted foods and microalbuminuria in children: the 2011 Taiwan food scandal. Environ Int. 2016;89-90:129–37.
93. Huang HB, Kuo PH, Su PH, Sun CW, Chen WJ, Wang SL. Prenatal and childhood exposure to phthalate diesters and neurobehavioral development in a 15-year follow-up birth cohort study. Environ Res. 2019;172:569–77.
94. Galgani F, Hanke G, Maes T, Global distribution, composition and abundance of marine litter, in Marine Anthropogenic Litter. 2015. p. 29-56.
95. Japan Vinyl Environmental Council. Available from: http://www.vec.gr.jp/lib/lib2_1.html.
96. Fries et al. Identification of polymer types and additives in marine microplastic particles using pyrolysis-GC/MS and scanning electron microscopy. Environ Sci Process Impacts. 2013;15(10):1949–56.
97. Bakir A, O’Connor IA, Rowland SJ, Hendriks AJ, Thompson RC. Relative importance of microplastics as a pathway for the transfer of hydrophobic organic chemicals to marine life. Environ Pollut. 2016;219:65–72.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions